Buckingham Research Upgrades Allergen (AGN) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St futures flat after tech rout; Iran tensions, retail earnings in focus
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Global bond rout pauses as sovereign yields back off multi-decade highs
- Lowe's slashes full-year sales outlook amid DIY spending pressure
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
Analyst Comments on Allergen (AGN) as Investors Await Updated Valeant (VRX) Proposal
May 27, 2014 1:57 PM EDTWells Fargo maintained an Outperform rating on Allergen (NYSE: AGN). Analyst Larry Biegelsen expects Valeant Pharmaceuticals International (NYSE: VRX) to update its proposal tomorrow.
"VRX is expected to raise its bid for AGN tomorrow, perhaps including a higher cash component. We have to wait-n-see on the higher bid and AGN's ultimate response.... More
